In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Featured Stories

Synaffix’s Serial Dealmaker On ADC Platform Success And Expanding Into Gene Therapy

Anthony DeBoer, head of business development at Synaffix, joined the company in 2014 and has helped develop a platform technology business model in the antibody drug conjugate space, where Synaffix has become one of the leading technology providers enabling best-in-class therapeutic candidates.

Rising Leaders Strategy

Finger On The Pulse: The State Of Biopharma Leadership

In Vivo asked six biopharma figureheads to share their thoughts on the state of leadership in the life sciences space, exploring the qualities of a great leader, how recent years have shaped this role within the industry and the challenges ahead.

Leadership Business Strategies Companies

How To Be An Early-Stage Biotech CEO In Challenging Times

The ongoing downturn is making early-stage biotech leaders work harder to gain funding – but new technology, business focus and better working practices could help them achieve success. 

C-Suite Speaks Commercial Strategies Leadership

Latest Articles

Putting The Patient First: The Challenge And Opportunities To Improve Rare-Disease Therapy Development


Advances in identifying the genetic causes of diseases, and particularly cancers, coupled with regulatory incentives to encourage the development of therapeutic approaches to once poorly managed orphan diseases have fueled a surge in exciting new medicines. To address some of these issues and explore potential solutions, Simbec-Orion in collaboration with Informa Pharma Intelligence convened a round table of experts attending the BIO International Convention

Read More

Growth Explore this Topic

Set Alert for Growth

Latest From Growth

Deal-Making In 2023: Pharma Finds Value In Flexibility

Restricted financial avenues raised many open questions at the recent LSX World Congress about the kind of deals that will shape biopharma pipelines in the coming 12-18 months. 

Business Strategies Deals

Snapshot: March Highlights

A selection of articles you may have missed from March 2023, including discussion of the benefits and risks of both CAR-T and NK cell therapies, insights into how companies can source financing when VC cash is scarce, and a highlight on Pfizer's mammoth purchase of Seagen.

Medical Device BioPharmaceutical

Uzbekistan To Implement Large Pharma Projects

Uzbekistan is the most populous country in Central Asia with 36 million people. The country has the only plant in Central Asia specializing in insulin production for the treatment of diabetes. Uzbek authorities aim to develop 90 pharma projects worth $1.2bn by 2026.

Business Strategies Uzbekistan

Innovation Explore this Topic

Set Alert for Innovation

Latest From Innovation

Fostering a Culture of Innovation, From Evolutionary To Revolutionary

Innovation is a key to long-term success for biopharma companies, but building the right climate to foster creative problem-solving is challenging. Questioning assumptions and constraining the target of innovation can propel a company forward.

Innovation Leadership

Alife Health Leverages AI For IVF To Increase Access To Care And Chances Of Success

One in eight couples in the US are struggling to get pregnant. Alife Health’s CEO Paxton Maeder-York believes that by leveraging artificial intelligence for use in IVF fertility clinics, he can help shape a future where more people have a better chance of starting families at a lower cost and higher rate of success.

Rising Leaders Artificial Intelligence

Ovid Therapeutics: Seeking Innovation In Epilepsy Treatment

Rising Leader Julia Tsai wants to see Ovid Therapeutics become a market leading epilepsy company that listens to the needs of patients and develops innovative drugs to treat a spectrum of epileptic indications and symptoms.

Rising Leaders Commercial
Data Spotlight

Deals Of The Year 2022 Winners Revealed

For In Vivo's 15th annual Deals of the Year contest, we selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.

Dealmaking Quarterly Statistics, Q4 2022

During Q4, biopharma merger and acquisition value reached $35.7bn and drew in $62.1bn in potential deal value from alliances. Device company M&A values reached $19.2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $4.8bn.

Financing Quarterly Statistics, Q4 2022

During Q4, biopharmas brought in an aggregate $17.5bn in financing and device company fundraising totaled $1.9bn; while in vitro diagnostic firms and research tools players raised $848m.

Leadership Explore this Topic

Set Alert for Leadership

Latest From Leadership

Wave Of New Leaders Could Reshape Generics Industry

With a number of top generics and biosimilars firms announcing new leaders over the past few months, the industry could be in for some strategic shifts as new faces take the helm at established off-patent players.

Business Strategies Commercial

Fostering a Culture of Innovation, From Evolutionary To Revolutionary

Innovation is a key to long-term success for biopharma companies, but building the right climate to foster creative problem-solving is challenging. Questioning assumptions and constraining the target of innovation can propel a company forward.

Innovation Leadership

The E in ESG: Thermo Fisher On Why The ‘How’ Is More Important Than The ‘When’

Life sciences and diagnostics group Thermo Fisher Scientific is encouraging suppliers to meet the same ambitious climate change targets that it has set for itself – mindful that Scope 3 emissions account for the vast majority of industry’s environmental footprint. But the drive for compliance must not compromise achievements made in the “S in ESG,” says corporate VP, CSR and sustainability, Meron Mathias.

Leadership Sustainability

Market Access Explore this Topic

Set Alert for Market Access

Latest From Market Access

In Saudi Arabia, A Vision Of Healthcare Spurs Growth

As the Kingdom of Saudi Arabia reduces its dependence on oil as an export, one sector it is building up is the life sciences industry. The government is encouraging global companies to manufacture and invest domestically and they are improving their regulatory system and working with local players to enhance access to patients.

Saudi Arabia Emerging Markets

The E In ESG: Sustainability Goals Do Not Exempt Companies From Antitrust Compliance

Regulatory interventions are the preferred route for ensuring sustainability compliance, says the OECD. Legal firm CMS notes that some ESG objectives may be in contravention of antitrust law. The EU is preparing guidelines on horizontal competition with a renewed focus on sustainability.

Sustainability Market Access

‘Fail Quickly, Succeed Quickly’ – BioWales Profiles Value Proposition For Medtech Innovation

New policy initiatives and “can do” networking openness in Wales are persuading medtech and healthtech innovators to consider the merits of locating in Great Britain’s smallest home nation.

Market Access United Kingdom

Market Intelligence Explore this Topic

Set Alert for Market Intelligence

Latest From Market Intelligence

Dealmaking Quarterly Statistics, Q1 2023

During Q1, biopharma merger and acquisition deal value reached $51.9bn and drew in $38.1bn in potential deal value from alliances. Device company M&A values reached $4.8bn, while in vitro diagnostics and research tools players’ M&A activity totaled $2.7bn.

Deals Market Intelligence

Deals Shaping The Medical Industry, April 2023

In Vivo's deal-making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – acquisition, alliance, or financing. This month’s column covers deals announced in March 2023. Data provided by Biomedtracker.

Medical Device BioPharmaceutical

Pear Bankruptcy Filing Highlights Reimbursement Barriers for Digital Therapeutics

Pear Therapeutics, Inc. filed for Chapter 11 bankruptcy in April, saying that it had laid off about 92% of its staff but would still pursue a sale of the company or its assets. Health care insiders tell AIS Health, a division of MMIT, that the announcement by one of the pioneers in the prescription digital therapeutics industry highlights the challenges such companies face getting their products reimbursed. The difficulties are exacerbated by investors being wary of backing companies that promise future growth but have yet to turn a profit. 

Business Strategies Restructuring
UsernamePublicRestriction

Register